Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
4,738 people get MDT articles and Market Currents by email alert.
Get email alerts on MDT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
How Medtronic Could Justify A $55 Stock ValueTrefis • Thu, Feb 14
-
-
-
-
-
-
-
-
-
Medtronic's CEO Discusses F2Q 2013 Results - Earnings Call TranscriptTue, Nov 20, 2012
-
Medtronic's CEO Hosts 2012 Investor Conference (Transcript)Sat, Jun 2, 2012 • 2 Comments
-
Medtronic's CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, Feb 21, 2012
-
Medtronic's CEO Discusses Q2 2012 Results - Earnings Call TranscriptTue, Nov 22, 2011
-
Medtronic, Inc. Shareholder/Analyst CallThu, Aug 25, 2011
-
Medtronic's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, Aug 23, 2011
-
Medtronic's CEO Discusses Q3 2011 Results - Earnings Call TranscriptTue, Feb 22, 2011
-
Medtronic CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Nov 23, 2010
-
Medtronic CEO Discusses F1Q11 Results - Earnings Call TranscriptTue, Aug 24, 2010
-
Medtronic F4Q10 (Qtr End 04/30/2010) Earnings Call TranscriptTue, May 25, 2010
-
Medtronic F3Q10 (Qtr End 1/29/10) Earnings Call TranscriptTue, Feb 23, 2010
-
Medtronic Inc. F2Q10 (Qtr End 10/30/09) Earnings Call TranscriptTue, Nov 24, 2009
-
Medtronic, Inc. F1Q10 (Qtr End 07/31/09) Earnings Call TranscriptTue, Aug 25, 2009
-
at MarketWatch.com (Sun, 11:19AM)
-
at CNBC.com (Fri, 8:14AM)
-
at Fox Business (May 3, 2013)
-
at MarketWatch.com (Mar 1, 2013)
-
at CNBC.com (Feb 19, 2013)
-
at Fox Business (Feb 19, 2013)
-
at CNBC.com (Feb 19, 2013)
-
at MarketWatch.com (Feb 19, 2013)
-
at CNBC.com (Feb 19, 2013)
-
at MarketWatch.com (Feb 18, 2013)
-
at CNBC.com (Jan 23, 2013)
-
at CNBC.com (Jan 23, 2013)
-
at Fox Business (Jan 22, 2013)
-
at CNBC.com (Jan 3, 2013)
-
at CNBC.com (Dec 6, 2012)
-
at CNBC.com (Nov 21, 2012)
-
at CNBC.com (Nov 20, 2012)
-
at CNBC.com (Nov 19, 2012)
-
at MarketWatch.com (Nov 19, 2012)
-
at CNBC.com (Nov 16, 2012)
MDT vs. ETF Alternatives
Company Description
Medtronic is the global leader in medical technology — alleviating pain, restoring health, and extending life for millions of people around the world. We are committed to offering market-leading therapies to restore patients to fuller, healthier lives. With beginnings in the treatment of heart... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, April 22, 8:43 AM Arca Biopharma (ABIO) soars 35% premarket. The company says it will collaborate with Medtronic (MDT) on a Phase 2b clinical trial for Gencaro, ABIO's lead developmental drug for the treatment of cardiac rhythm disorders. Comment! [Healthcare, On the Move]
- Thursday, April 11, 1:48 PM Medtronic (MDT +1.3%) moves up today after saying it's initiated enrollment of the first patient in its SubQStim II clinical trial which uses peripheral nerve stimulation, also known as subcutaneous nerve stimulation, to reduce chronic, intractable post-surgical back pain. Comment! [Healthcare, On the Move]
- Wednesday, January 30, 9:29 AM ARCA Biopharma (ABIO) +51.9% premarket after announcing plans for a phase 3 adaptive design clinical trial for its lead developmental drug, Gencaro, in atrial fibrillation. Medtronic (MDT) will be collaborating on the initial, phase 2B portion of the proposed trial. Comment! [Healthcare, On the Move]
- Thursday, January 17, 3:58 PM Medtronic (MDT +3%) posts a healthy gain today after Credit Suisse ups the shares to Outperform and raised its price target from $47 to $50. The firm cites "sustainable improvement" in top-line growth and a healthy revamp of its strategic directives. 1 Comment [Healthcare, On the Move]
- Tuesday, January 15, 2:22 PM Boston Scientific (BSX +2.5%) hits a 16-month high today after Credit Suisse upped the stock to Outperform, citing a better top-line and improved visibility. On those catalysts, the firm reduces the valuation discount it thinks the stock should trade at versus rivals St. Jude (STJ) and Medtronic (MDT) to 10%. The stock currently trades at around a 20% discount to its peers. Comment! [Healthcare, On the Move]
- Friday, December 21, 2012, 3:24 PM The FDA says it recalled Medtronic's (MDT -1.4%) SynchroMed II and SynchroMed EL implantable drug infusion pumps back in November, saying that the use of unapproved drugs can lead to "intermittent or permanent pump motor stall and cessation of drug infusion." The overall failure rate of the SynchroMed II pump at 78 months post implant is 2.4% when used to dispense approved drugs, but it climbs to 7.0% when used to dispense unapproved drugs. Comment! [Healthcare, On the Move]
- Monday, November 26, 2012, 11:01 AM Boston Scientific (BSX +2.7%) bucks a down tape this morning on an upgrade to Buy at Citigroup. The firm says BSX is positioned to be the biggest winner from St. Jude Medical's (STJ -1%) Durata troubles. Citi expects it will be taken off the market within six months, and the ripple effects are likely to cost STJ around $820M in annual sales. BSX could easily take 41% of that market share, with Medtronic (MDT -0.9%) absorbing around 29%. Citi's upgrade differs widely from comments made on Friday by BofA Merrill, which put the risk of a Durata recall well below 50%. Comment! [Healthcare, On the Move]
- Monday, November 19, 2012, 2:23 PM St. Jude Medical (STJ +2%) says its received European approval for its Portico heart valve replacement device. The approval gives STJ access to a burgeoning market for the devices, and the news gives a much-needed lift to the stock after a string of negative headlines in recent months has driven the stock down near 52-week lows. Since October alone, STJ has shaved nearly 17% off its market cap. Comment! [Healthcare, On the Move]
- Thursday, June 28, 2012, 11:32 AM The Supreme Court opinion on the Healthcare Act means that medical device makers still face a 2.3% tax on domestic sales starting next year unless they can persuade Congress to repeal it. Shares are sliding: MDT -1.2%, BSX -2.7%, STJ -1%, EW 1.1%, SYK -1.9%, ATRC -4.7%, CYBX -1.6%. 1 Comment [Healthcare, On the Move]
- Monday, April 30, 2012, 1:20 PM Medtronic (MDT +1.2%) gains after being upgraded to Buy on valuation earlier today at Lazard Capital, citing the company's new product growth potential. Comment! [Healthcare, On the Move]
- Monday, April 9, 2012, 2:33 PM St. Jude Medical (STJ -4.8%) shares sink after calling attention to a medical journal article that shows Medtronic's (MDT -0.9%) heart device leads resulted in fewer deaths than its recalled Riata and Riata ST products. STJ says the article "substantially undercounted" deaths associated with MDT's Quattro Secure device and wants it retracted. Comment! [Healthcare, On the Move]
- Friday, March 9, 2012, 2:52 PM Medtronic (MDT -1.1%) dips after Argus cut the shares to Sell earlier today, citing concerns regarding slowing sales growth and its three largest franchises, which is being driven by secular factors rather than cyclical. Comment! [Tech, On the Move]
- Wednesday, February 22, 2012, 3:26 PM Analysts at Credit Suisse and Deutsche Bank downgrade stock ratings for Medtronic (MDT -2%), as the medical device maker deals with a slowdown in some of its end markets. Some 60% of MDT’s current sales are in declining or low growth markets, CS says; DB is concerned that the company will have trouble growing in the near term. Comment! [Healthcare, On the Move]
- Tuesday, February 21, 2012, 1:23 PM Shares of Medtronic (MDT -2.7%) drift lower after missing on its FQ3 earnings earlier today. Revenues actually rose marginally Y/Y, as the medical-device maker benefited from fewer charges and the impact of divesting its Physio-Control business. The company also narrowed its per-share earnings estimate for the year, now expecting to earn between $3.44 - $3.47 versus earlier estimates of $3.43 - $3.50. Comment! [Healthcare, On the Move]
- Thursday, January 26, 2012, 11:39 AM NuVasive (NUVA -5.5%) drops back down after racking up a double-digit gain yesterday when a federal court denied Medtronic's (MDT -0.3%) request for a permanent inunction. It's not the end of the road for the company with more courtroom battles upcoming to see if it will have to pay a $101M jury award for patent infringement. Comment! [Healthcare, On the Move]
- Thursday, December 29, 2011, 2:52 PM Medtronic (MDT +2.6%) moves higher after Citigroup chooses the company as its top pick among medical device companies for 2012 and hikes its price target to $44 from $40. Citi believes MDT’s lagging ICD and spinal hardware segments should rebound in 2012, and new gadgets, including pacemakers, should help boost growth. 1 Comment [Healthcare, On the Move]
-
The Aristos
$MDT needs to increase dividend to $.30+ to maintain pace of stock price. No longer a great dividend stock in my eyes at a 2% yield. - View all 4 replies
-
Dividend Growth Machine: Understood. I'm guessing they'll do a 7.7% increase to $0.28 per share, which would be satisfactory for me (I am long MDT). -
The Aristos: Was long from early 2012. Sold in April. Probably over-thinking it yet put that money in more undervalued names.
-
- View all 0 replies
-
Dividend Sheet
$TROW $FTR and $HCP are the most profitable Dividend Champions - http://stks.co/dTVp - 20 shares with 2.6% average yield $SIAL $MDT $MHFI - View all 0 replies
-
Dividend Sheet
$PDLI $WCRX and $QCOR are the best Yielding Cheap Healthcare Dividend Stocks - http://stks.co/dSSu - 20 stocks 2.66% at Yield $MDT $PFE - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
-
-
- View all 2 replies
-
Kwimo: It's just an add to a long term position that I've had since last summer. This portion won't be long term.
-
-
- View all 0 replies
-
Tony Kau
Lots of viable Put credit spreads right now... $POT $CF $JWN $WLT $MDT $DDS http://stks.co/aLoe http://ow.ly/i/1A9HR - View all 2 replies
-
SKS1586: Awesome stock list TONY. Good-Luck to create 100% winners (IMO possibility is near 100%)
-
Tony Kau: Thanks! Yes, trying to get in always 85%+, usually 90%+ chance of profit, with decent premiums... Cheers!
LATEST REPLIES
-
The Aristos
$MDT needs to increase dividend to $.30+ to maintain pace of stock price. No longer a great dividend stock in my eyes at a 2% yield. - View all 4 replies
-
Dividend Growth Machine: Understood. I'm guessing they'll do a 7.7% increase to $0.28 per share, which would be satisfactory for me (I am long MDT).
-
The Aristos: Was long from early 2012. Sold in April. Probably over-thinking it yet put that money in more undervalued names.
-
- View all 2 replies
-
-
-
- View all 2 replies
-
Kwimo: It's just an add to a long term position that I've had since last summer. This portion won't be long term.
-
-
Tony Kau
Lots of viable Put credit spreads right now... $POT $CF $JWN $WLT $MDT $DDS http://stks.co/aLoe http://ow.ly/i/1A9HR - View all 2 replies
-
SKS1586: Awesome stock list TONY. Good-Luck to create 100% winners (IMO possibility is near 100%)
-
Tony Kau: Thanks! Yes, trying to get in always 85%+, usually 90%+ chance of profit, with decent premiums... Cheers!
-
- View all 4 replies
-
-
Dr. Kris: Bob: I'm dubbing you the official SA music director. Each stock should have its own theme song.
-
Ryan Mallory
Long Medtronic (MDT) at $38.15 and the pain in suffering of selling AUTH just before the AAPL buyout http://bit.ly/LSa612 - View all 11 replies
-
-
-
- View all 14 replies
-
-
-
- View all 6 replies
-
-
-
- View all 2 replies
-
-